- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02474264
The Link Between BRCA Mutation and Endothelial Function
July 13, 2017 updated by: Rabin Medical Center
The Link Between BRCA Mutation and Endothelial Function - A Pilot Study
This study evaluates the effect of BRCA1&2 mutations on cardiovascular diseases by to comparing the endothelial function of male BRCA mutation carriers with that of age matched non-BRCA mutation carriers.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
82
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: David Margel, MD, PhD
- Phone Number: +972(0)39376553
- Email: sdmargel@gmail.com
Study Locations
-
-
-
Petah Tikva, Israel
- Recruiting
- Rabin Medical Center, Beilinson Hospital
-
Contact:
- David Margel, MD PhD
- Phone Number: +972(0)39376553
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Known carrier or non-carrier, confirmed by genetic testing of BRCA 1/2 mutation
- Able and willing to sign an informed consent
Exclusion Criteria:
- History of, or current, malignancy
History of:
- Myocardial infarction
- Ischemic or Hemorrhagic cerebrovascular conditions
- Arterial embolic and thrombotic events
- Ischemic heart disease
- Prior coronary artery or ilio-femoral artery revascularization (percutaneous or surgical procedures)
- Peripheral vascular disease (e.g. claudication, prior vascular surgery/intervention)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SCREENING
- Allocation: NON_RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: male BRCA mutations carriers
Endothelial function assessment and Cardiovascular biomarkers
|
reactive hyperemia index
Cardiovascular biomarkers will be measure to test other aspects of endothelial and cardiac function: high-sensitivity troponin (hsTn) , C-reactive protein , D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP)
Endothelial Progenitor Cells and Circulating Endothelial Cells profiles- will be characterized to evaluate endothelial injury.
|
OTHER: healthy males - control group
Endothelial function assessment and Cardiovascular biomarkers
|
reactive hyperemia index
Cardiovascular biomarkers will be measure to test other aspects of endothelial and cardiac function: high-sensitivity troponin (hsTn) , C-reactive protein , D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP)
Endothelial Progenitor Cells and Circulating Endothelial Cells profiles- will be characterized to evaluate endothelial injury.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
reactive hyperemia index will be assessed using the Endo-PAT2000
Time Frame: at baseline
|
will be assessed using the Endo-PAT2000
|
at baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The level of high sensitivity troponin (hsTn) - a cardiovascular risk biomarker will be measured
Time Frame: at baseline
|
high sensitivity troponin (hsTn)
|
at baseline
|
The level of C-reactive protein - a cardiovascular risk biomarker will be measured
Time Frame: at baseline
|
C-reactive protein
|
at baseline
|
The level of D-dimer - a cardiovascular risk biomarker will be measured
Time Frame: at baseline
|
D-dimer
|
at baseline
|
The level of N-terminal pro-brain natriuretic peptide (NT-proBNP) - a cardiovascular risk biomarker will be measured
Time Frame: at baseline
|
N-terminal pro-brain natriuretic peptide (NT-proBNP)
|
at baseline
|
Endothelial Progenitor Cells profile (EPC) - will be characterized to evaluate endothelial injury.
Time Frame: at baseline
|
Endothelial Progenitor Cells (EPC)
|
at baseline
|
Circulating Endothelial Cells profile (CEC) - will be characterized to evaluate endothelial injury.
Time Frame: at baseline
|
Circulating Endothelial Cells (CEC)
|
at baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: David Margel, MD, PhD, Rabn Medical Center, Beilinson Campus
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (ANTICIPATED)
July 1, 2018
Study Completion (ANTICIPATED)
November 1, 2018
Study Registration Dates
First Submitted
February 23, 2015
First Submitted That Met QC Criteria
June 12, 2015
First Posted (ESTIMATE)
June 17, 2015
Study Record Updates
Last Update Posted (ACTUAL)
July 18, 2017
Last Update Submitted That Met QC Criteria
July 13, 2017
Last Verified
October 1, 2016
More Information
Terms related to this study
Other Study ID Numbers
- 0594-14-RMC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BRCA1 Gene Mutation
-
Ohio State University Comprehensive Cancer CenterRecruitingBRCA1 Gene Mutation | BRCA2 Gene MutationUnited States
-
University of California, San FranciscoAmerican Cancer Society, Inc.CompletedBRCA1 Gene Mutation | BRCA2 Gene MutationUnited States
-
Pamela MunsterNational Cancer Institute (NCI)Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene MutationUnited States
-
University of California, San FranciscoGlaxoSmithKlineRecruitingMetastatic Solid Tumor | BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene MutationUnited States
-
Rabin Medical CenterCompletedBRCA1 Gene Mutation | BRCA2 Gene MutationIsrael
-
University Medical Center NijmegenRecruitingOvarian Cancer | BRCA1 Gene Mutation | BRCA2 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene MutationNetherlands, United States, Belgium, Norway, Poland, Italy, Australia, Mexico, Brazil, Sweden, Uruguay
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6... and other conditionsUnited States
-
Marc Dall'Era, MDNational Cancer Institute (NCI); Janssen, LPRecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Prostate Carcinoma | RAD51C Gene Mutation | BRIP1 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CDK12 Gene Mutation | CHEK1 Gene Mutation | DNA Damage Response Gene Mutation | DNA Repair Gene Mutation | FANCA Gene Mutation and other conditionsUnited States
-
Beth Israel Deaconess Medical CenterJohns Hopkins University; Dana-Farber Cancer Institute; AstraZenecaActive, not recruitingMetastatic Breast Cancer | Invasive Breast Cancer | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | Somatic Mutation Breast Cancer (BRCA1) | Somatic Mutation Breast Cancer (BRCA2)United States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedBRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | ATR Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CHEK1 Gene Mutation | FANCA Gene... and other conditionsUnited States, Canada
Clinical Trials on Endothelial function assessment
-
Hopital FochCompletedPulmonary FibrosisFrance
-
Memorial Sloan Kettering Cancer CenterCompletedHigh Risk for Postoperative Cardiovascular EventsUnited States
-
M.D. Anderson Cancer CenterCompletedAbdominal Surgery | Thoracic SurgeryUnited States
-
Peking UniversityMayo Clinic; Peking University Shougang HospitalRecruitingNon-obstructive Coronary Artery DiseaseChina
-
HaEmek Medical Center, IsraelTerminated
-
Ospedale San Giovanni BellinzonaCompletedTakotsubo Cardiomyopathy | Syndrome XSwitzerland
-
Centre Hospitalier Universitaire, AmiensCompletedAortic Valve Disease | Endothelial DysfunctionFrance
-
University of ExeterNorth Bristol NHS Trust; Royal Devon and Exeter NHS Foundation Trust; Royal United...Not yet recruitingInterstitial Lung Disease
-
National Institute of Cardiology, Laranjeiras,...CompletedObesity | DyslipidemiasBrazil
-
National Institute of Cardiology, Laranjeiras,...RecruitingEndothelial Dysfunction | Arterial Hypertension | Resistant Hypertension | Microvascular RarefactionBrazil